DelNova’s partnership will enable clinical development of its lead candidate ReViVox® for the rescue of undesirable outcomes which may arise from a botulinum neurotoxin (BoNT) treatment such as Botox®. Pace® Life Sciences provides a full suite of contract CMC development, clinical trials…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.